The global market for ANA testing is projected to grow from USD 823.5 million in 2016 to USD 1,476 million by 2021, driven by factors such as the increasing incidence of autoimmune diseases and rising healthcare spending. While a positive ANA test indicates potential autoimmune conditions, it is not definitive proof of any disease, as positive results can be influenced by various factors, including age and other health issues. Clinicians are advised to exercise caution in diagnosing based solely on ANA results and ensure thorough patient evaluation.